Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex

American Journal of Kidney Diseases

Volumn 69, Issue 6, 2017, Pages 771-779

  Winkelmayer, Wolfgang C ^a   Goldstein, Benjamin A ^b   Mitani, Aya A ^c   Ding, Victoria Y ^d   Airy, Medha ^a   Mandayam, Sreedhar ^a   Chang, Tara I ^d   Brookhart, M Alan ^e   Fishbane, Steven ^f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University of North Carolina at Chapel Hill   (United States)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

cardiovascular; dialysis facility formulary; end stage renal disease (ESRD); hemodialysis; infectious hospitalization; Intravenous iron; iron sucrose; mortality; myocardial infarction; natural experiment; safety; sodium ferric gluconate complex; stroke

Indexed keywords

FERRIC GLUCONATE; IRON SACCHARATE; ANTIANEMIC AGENT; FERRIC ION; FERRIC OXIDE, SACCHARATED; SACCHARIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HEART INFARCTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT CARE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; ANEMIA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMPARATIVE STUDY; COMPLICATION; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL;

ADMINISTRATION, INTRAVENOUS; AGED; ANEMIA; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; FERRIC COMPOUNDS; GLUCARIC ACID; HEMATINICS; HUMANS; INFECTION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 85008506993     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.10.031     Document Type: Article

References (18)

1. Macdougall, I.C., Bircher, A.J., Eckardt, K.U., et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 89 (2016), 28–39.
2. Yang, J.Y., Lee, T.C., Montez-Rath, M.E., et al. Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol 23 (2012), 495–506.
3. Markowitz, G.S., Kahn, G.A., Feingold, R.E., Coco, M., Lynn, R.I., An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 48 (1997), 34–40.
4. Danielson, B.G., Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 15:suppl 2 (2004), S93–S98.
5. Sirken, G., Raja, R., Rizkala, A.R., Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients. Clin Nephrol 66 (2006), 348–356.
6. Brookhart, M.A., Freburger, J.K., Ellis, A.R., Winkelmayer, W.C., Wang, L., Kshirsagar, A.V., Comparative short-term safety of sodium ferric gluconate versus iron sucrose in hemodialysis patients. Am J Kidney Dis 67 (2016), 119–127.
7. Ishida, J.H., Marafino, B.J., McCulloch, C.E., et al. Receipt of intravenous iron and clinical outcomes among hemodialysis patients hospitalized for infection. Clin J Am Soc Nephrol 10 (2015), 1799–1805.
8. Winkelmayer, W.C., Chang, T.I., Mitani, A.A., et al. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis 66 (2015), 106–113.
9. Airy, M., Mandayam, S., Mitani, A.A., et al. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. Nephrol Dial Transplant 30 (2015), 2068–2075.
10. Tirschwell, D.L., Longstreth, W.T. Jr., Validating administrative data in stroke research. Stroke 33 (2002), 2465–2470.
11. Kiyota, Y., Schneeweiss, S., Glynn, R.J., Cannuscio, C.C., Avorn, J., Solomon, D.H., Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 148 (2004), 99–104.
12. Brookhart, M.A., Freburger, J.K., Ellis, A.R., Wang, L., Winkelmayer, W.C., Kshirsagar, A.V., Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 24 (2013), 1151–1158.
13. Austin, P.C., Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28 (2009), 3083–3107.
14. Montez-Rath, M.E., Winkelmayer, W.C., Desai, M., Addressing missing data in clinical studies of kidney diseases. Clin J Am Soc Nephrol 9 (2014), 1328–1335.
15. Parkkinen, J., von Bonsdorff, L., Peltonen, S., Gronhagen-Riska, C., Rosenlof, K., Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15 (2000), 1827–1834.
16. Fuller, D.S., Pisoni, R.L., Bieber, B.A., Port, F.K., Robinson, B.M., The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis 62 (2013), 1213–1216.
17. Bailie, G.R., Larkina, M., Goodkin, D.A., et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 87 (2015), 162–168.
18. Wang, C., Graham, D.J., Kane, R.C., et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 314 (2015), 2062–2068.